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Editorial on the Research Topic
Interactions of the Nervous SystemWith Bacteria
Recent evidence that microbes influence mood and behavior via the gut-brain axis has opened
up new avenues for research into neurological disorders. Hence, many studies now employ
multidisciplinary approaches assessing for changes in microbial diversity, neuroinflammation as
well as alterations in neuronal circuitry that impact brain function in health and disease. Such
collaborative research was virtually unheard of in previous decades but holds remarkable promise
for identifying novel pathways and therapeutic targets within the gastrointestinal tract to treat brain
disorders. This editorial highlights these exciting developments in neuroscience, microbiology, and
immunological research by examining 13 articles focused on how the nervous system interacts
with bacteria in preclinical and clinical settings. A common theme is the dissection of complex
interactions between the nervous system and bacteria as well as the resulting influences on
inflammatory pathways, symptoms, or behavior in patient studies and mouse models. Specifically,
neuronal-microbial interactions in the context of nervous system disorders ranging from autism,
Attention Deficit Hyperactivity Disorder, Alzheimer’s Disease and Major Depressive Disorder to
migraine and epilepsy are investigated. Overall, we propose that via leveraging our understanding
of the gut-brain axis, the modulation of gut microbes leading to significant benefits for brain health
can become a reality.
The recent years have seen substantial progress in the understanding of gut-brain interactions.
Today, evidence ismounting that themicrobiota-gut-brain axis is a key contributor to healthy brain
development and function. Accordingly, gastrointestinal (GI) problems and microbial dysbiosis
have been linked to several neurological and neuroinflammatory disorders. Consequently, targeting
gut microbiota composition to regulate peripheral and central inflammation could serve as means
of developing novel treatments or disease modifying strategies for several key neuroinflammatory
conditions. This is a rapidly emerging field of neuroscience research and is highlighted in the
current issue.
This Research Topic is dedicated to understanding the influence of microbes on brain health.
Alterations in the gut microbiota may affect gut-brain signaling via neuronal, endocrine and
immunological mechanisms, thereby influencing a range of neuronal network activities and
ultimately host behaviors. Zhao et al. showed that emotional behavior is among those behaviors
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affected. Antibiotic-treated mice with a lower richness
and diversity of microbiota display increased anxiety-like,
depression-like, and aggressive behaviors (Zhao et al.). These
effects on behavior may be caused by a dysregulation of
the immune and endocrine system. In line with this, a link
between altered microbiota composition and immune system
abnormalities was also reported by Sauer and Grabrucker. In
their study, a deficiency in the essential trace metal, zinc, changed
the composition of the microbiota. Of interest, zinc deficiency
has been linked to depression-like behavior in rodents. In this
study, the microbial changes were accompanied by increased
inflammatory cytokine levels. Furthermore, this study reported
abnormal GI morphology and increased GI permeability
in these mice, hinting that an increase in intestinal barrier
permeability may mediate pro-inflammatory processes (Sauer
and Grabrucker).
Relevant to the findings of Sauer and Grabrucker, the role
of microbes in modifying the permeability of the mucosal
epithelium lining the GI tract was discussed in a review of
microbiome-derived neurotoxins by Lukiw. How microbiota
might impact the properties of the mucus membrane in the GI
tract could also be important in brain disorders. Lukiw discussed
the role of the zinc metalloproteinase (also known as B. fragilis
Toxin; BFT or fragilysin), which is released by Bacteroides fragilis
microbes. Fragilysin cleaves tight junction components such
as cadherins which can alter the permeability of mucosal and
blood-brain barriers. This action would also alter neuro-immune
interactions and is age-related and progressive. An important
part of the epithelial barrier of the GI tract is the mucus biofilm,
which provides a supportive environment for specific microbial
populations. Because patients with many neurological diseases
have GI issues andmicrobial dysbiosis, Herath et al., reviewed the
evidence for mucus as a potential treatment target in the context
of neurological disease (Herath et al.). This review outlined a
range of pathways by which gene mutations associated with
brain disorders could influence the GI tract’s mucus and its
microbial populations.
Sharna and colleagues investigated neuro-immune
interactions in a mouse model of autism expressing a gene
mutation in the nervous system (Sharna et al.). Surprisingly,
the weight of the caecum (the equivalent of the human
appendix) was reduced in these mice. When analyzing the
enteric nervous system in the caecum, mutant mice had
more neurons overall and a higher proportion of neurons
synthesizing the major inhibitory neurotransmitter (nitric
oxide) of the gut. In the same study, Sharna and coauthors
found changes in the gut immune system. In these mice,
macrophages were labeled with Iba-1 (a marker of microglia in
the brain) in the gut-associated lymphoid tissue of the caecal
patch. Mutant mice had more Iba-1 labeled macrophages,
and these macrophages were smaller and rounder in shape.
Interestingly, this could indicate increased immune activity in
the autism model. More broadly, these findings suggest that
communication between the nervous system and immune
cells could be altered in neurological disorders such as autism,
and that the gut microbiota plays a key role in regulating
such interactions.
Further evidence of the nervous system’s interactions and
inflammatory pathways in brain disorders include a role for
lipopolysaccharide (LPS), lifestyle factors, and both the oral and
GI microbiome in Alzheimer’s Disease. The accumulation of gut
bacteria-derived LPS in neurons is associated with Alzheimer’s
disease. Lukiw et al. report that LPS entry into human neurons is
facilitated by amyloid beta-42 (Aβ42) and discuss the associated
pathogenic role of LPS in neurons of Alzheimer’s disease brains
(Lukiw et al.). The encapsulation of neurons by LPS reduces
the release of mRNA from the neuronal nuclei, likely via the
interaction of Aβ42 with nuclear pore complexes. Therefore,
manipulating the gut microbiome by diet and pre/probiotics to
reduce neurotoxic effects within the CNS is an exciting avenue
for future research. In line with these findings, Askarova and
colleagues brought together a wide range of research to link
the brain-gut-microbiota axis and Alzheimer’s Disease (Askarova
et al.). These authors noted that several lifestyle factors linked
to Alzheimer’s disease also drive microbiome changes, such as
dietary habits, sedentary behavior, and disturbances in circadian
rhythms. Changes in the oral microbiome in addition to chronic
periodontitis have also been associated with Alzheimer’s Disease
(Paganini-Hill et al., 2012; Harding et al., 2017; Liu et al., 2019;
Panza et al., 2019; Olsen and Singhrao, 2020). Given the potential
for factors within the gastrointestinal tract to contribute to
the development of neuroinflammation and neurodegeneration,
further studies are warranted.
Gut microbiota profiles may contribute to behavioral
symptoms associated with a range of neurological disorders,
including attention-deficit/hyperactivity disorder (ADHD) and
major depressive disorder (MDD). Wan et al. investigated the
gut microbiota in children with ADHD. Their results of a
case-control study reveal that specific bacteria are significantly
increased or decreased in children with ADHD and align
with alterations in neurotransmitter metabolic pathways (Wan
et al.). However, as Isaiah et al. point out, in addition to
the gut signaling to the brain, the reverse (i.e., brain-to-gut
signaling) may occur as well (Isaiah et al.), a phenomenon
that is currently understudied in the context of ADHD. Yong
et al. discussed the role of the microbiota-gut-brain axis, stress,
and lifestyle factors for major depressive disorder (MDD)
(Yong et al.). The antidepressive effects of probiotics and
potential biological mechanisms (including the production of
metabolites) to benefit gut health were compared in clinical
and animal studies. In addition, Westfall and Pasinetti discussed
the role of dietary polyphenols as a possible diseases-modifying
treatment for depression (Westfall and Pasinetti). Their review
highlighted that synbiotics that combine probiotics with dietary
polyphenols such as those found in fruits, tea, herbs, cereal,
or wine might be a novel therapy for MDD. This may occur
via modulation of multiple metabolic pathways, including the
breakdown of kynurenic acid and tryptophan (with influences
on glutamatergic activity and microglial function in the brain),
serotonergic mechanisms, and immune pathways, including via
interferon-gamma and inflammasome activation. Importantly,
these authors highlight that the heterogeneity of MDD must
be taken into consideration when evaluating the potential
therapeutic effects of probiotics.
Frontiers in Neuroscience | www.frontiersin.org 2 April 2021 | Volume 15 | Article 682744
Hill-Yardin et al. Editorial: Interactions Between Neurons and Bacteria
Migraine is a common, recurrent, and disabling neurological
disorder that is associated with alterations in the neurovascular
and immunological system. The changes in the nervous system
activity that occur in the setting of migraine are commonly
associated with gut disorders such as irritable bowel syndrome
and inflammatory bowel disease. Chen and others examined
the potential for interactions between the nervous system and
bacteria in their study of fecal samples from 108 elderly
women with and without migraine, which revealed a significant
decrease in species diversity and metabolic functions in the gut
microbiota of migraine sufferers. These findings suggest that
monitoring harmful bacteria such as Clostridium could help with
alteration of migraine frequency and potentially even prevention
of disease (Chen et al.). Future randomized control trials that
assess the efficacy of controlled delivery of “safer” and “less
inflammatory” microbiota as a means of controlling migraine
frequency are warranted.
Epilepsy is another neurological disorder for which a role
for the microbiome is understudied. The ketogenic diet is
commonly used to treat medically refractive seizures and
epilepsy. Importantly the anti-seizure effects of the ketogenic
diet are thought to be mediated by the gut microbiome (Olson
et al., 2018). Altering the gut bacteria is thought to regulate
seizure frequency and modify disease severity. Rubin and Glazer
outlined a potential role for subclinical infection with Bordetella
pertussis (BP) in epilepsy (Rubin and Glazer). This work
highlighted that cases of subclinical infection are vastly more
prevalent than reported pertussis cases and describe incidences
of epilepsy occurring after BP infection. Further research into
the relationship between epilepsy and BP infection, including BP
screening, medical history, and pertussis vaccination is required
to assess for an association between BP and seizures.
In summary, this Research Topic brings together evidence for
microbial influences in a range of neurological, neuropsychiatric
and neurodegenerative disorders including autism, Alzheimer’s
Disease, Major Depressive Disorder, migraine, and epilepsy. Gut
microbiota are thought to influence not only local immunological
processes, but also exert effects on the CNS through the
disruption of the gastrointestinal mucosal barrier and BBB. The
future of gut-brain research holds promise for identifying novel
therapeutic approaches to treat many disabling CNS conditions
traditionally considered to be associated with dysfunction of the
CNS itself. Further research into how modifying gut microbes
influence processes in the brain has enormous potential.
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